Skip to main content

Table 2 Outcome of body composition components, handgrip strength, health-related quality of life and biochemical measurements

From: Effects of protein-rich nutritional supplementation and bisphosphonates on body composition, handgrip strength and health-related quality of life after hip fracture: a 12-month randomized controlled study

 

Months

All patients

Group N

Group B

Group C

p-value

Body mass, kg (SD)

a0-6

−2.1 (3.5)

−2.0 (3.5)

−3.0 (3.8)

−1.2 (3.2)

0.29

b0-12

−1.6 (4.0)

−1.8 (3.0)

−2.2 (4.6)

−0.9 (4.1)

0.69

FFM, kg (SD)

a0-6

−1.5 (2.5)

−2.4 (2.0)

−1.3 (3.2)

−1.0 (1.9)

0.09

b0-12

−1.6 (2.7)

−2.2 (2.5)

−1.4 (3.2)

−1.3 (2.2)

0.41

FM, Kg (SD)

a0-6

−0.6 (2.9)

+0.4 (2.3)

−1.7 (3.6)

−0.2 (2.1)

0.06

b0-12

−0.2 (3.4)

+0.4 (2.1)

−0.7 (4.4)

−0.1 (3.0)

0.64

aLM, kg (SD)

a0-6

−0.1 (1.6)

−0.7 (1.4)

+0.3 (1.9)

+0.02 (1.4)

0.06

b0-6

−0.2 (1.6)

−0.4 (1.5)

−0.02 (2.0)

−0.2 (1.4)

0.40

FFMI, kg/m2 (SD)

a0-6

−0.6 (0.9)

−0.9 (0.7)

−0.4 (1.2)

−0.4 (0.8)

0.08

b0-12

−0.6 (1.0)

−0.8 (0.9)

−0.5 (1.2)

−0.5 (0.8)

0.31

FMI

a0-6

−0.2 (1.1)

0.1 (0.8)

−0.6 (1.4)

−0.1 (0.8)

0.06

kg/m2 (SD)

b0-12

−0.1 (1.2)

0.1 (0.8)

−0.3 (1.6)

−0.1 (1.1)

0.62

aLMI

a0-6

0.0 (0.6)

−0.2 (0.5)

+0.1 (0.7)

0.0 (0.6)

0.03

kg/m2 (SD)

b0-12

−0.1 (0.6)

−0.2 (0.5)

0.0 (0.7)

−0.1 (0.5)

0.30

HGS, kg (SD)

c0-6

1.4 (4.8)

2.6 (4.7)

−0.3 (4.0)

2.2 (5.4)

0.09

d0-12

−1.0 (5.8)

−0.06 (6.6)

−3.0 (6.1)

−0.2 (5.7)

0.22

EQ-5Dindex (SD)

c6

0.77 (0.23)

0.75 (0.32)

0.76 (0.20)

0.78 (0.19)

0.57

 

d12

0.74 (0.23)

0.76 (0.22)

0.70 (0.25)

0.75 (0.24)

0.60

S-IGF-I,μg/L (range)

6

124 (31–280)

124 (39–265)

135 (45–280)

117 (31–236)

0.39

 

12

119 (45–310)

111 (45–205)

137 (68–310)

129 (66–202)

0.35

S-IGF-I, SD score

6

0.4

0.4

0.6

0.1

0.42

12

0.2

0.1

0.7

0.4

0.58

P-Alb, g/L (range)

6

38 (24–47)

37 (28–46)

38 (24–42)

39 (33–47)

0.48

12

38 (28–46)

40 (29–46)

37 (34–45)

39 (33–45)

0.31

B-Hgb, g/L (range)

6

134 (107–171)

136 (110–171)

134 (113–160)

132 (107–154)

0.89

12

136 (109–162)

136 (109–162)

134 (115–153)

136 (115–151)

0.84

S-CRP, mg/L (range)

6

0 (0–48)

4 (0–32)

0 (0–48)

0 (0–17)

0.15

12

1 (0–21)

2 (0–21)

1 (0–8)

1 (0–6)

0.24

P-Creatinine, μmol/L (range)

6

71 (41–173)

67 (41–123)

76 (55–117)

72 (50–173)

0.38

12

73 (41–173)

67 (43–127)

80 (57–128)

71 (49–118)

0.19

  1. Group N = protein and energy supplementation for 6 months, and risedronate, vitamin D and calcium for 12 months, B = risedronate, vitamin D and calcium for 12 months, C = vitamin D and calcium for 12 months. Body mass (lean mass, fat mass and bone mineral content); FFM, fat free mass; FM, fat mass; aLM, appendicular lean mass; FFMI, fat free mass index; FMI, fat mass index; HGS, handgrip strength; EQ-5Dindex, the 5-Dimentional Scale of the HRQoL; S-IGF-I, serum-insulin growth factor-I; P-Alb, plasma-Albumin; B-Hgb, blood-Hemoglobin; S-CRP, serum-C-reactive protein; P-Creatinine, plasma-Creatinine. Data are given as mean (SD) or median (range). aPatients analyzed 0–6 months in group N, n = 19; group B, n = 25; group C, n = 24. bPatients analyzed 0–12 months in group N, n = 18; group B, n = 25; Group C; n = 23. cPatients analyzed 0–6 months in group N, n = 20; group B, n = 25; group C, n = 25. dPatients analyzed 0–12 months in group N, n = 18; group B, n = 25; group C, n = 21
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us